These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 8731095)

  • 1. Advanced oxidation protein products as a novel marker of oxidative stress in uremia.
    Witko-Sarsat V; Friedlander M; Capeillère-Blandin C; Nguyen-Khoa T; Nguyen AT; Zingraff J; Jungers P; Descamps-Latscha B
    Kidney Int; 1996 May; 49(5):1304-13. PubMed ID: 8731095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.
    Witko-Sarsat V; Friedlander M; Nguyen Khoa T; Capeillère-Blandin C; Nguyen AT; Canteloup S; Dayer JM; Jungers P; Drüeke T; Descamps-Latscha B
    J Immunol; 1998 Sep; 161(5):2524-32. PubMed ID: 9725252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and spectrophotometric significance of advanced oxidized protein products.
    Capeillère-Blandin C; Gausson V; Descamps-Latscha B; Witko-Sarsat V
    Biochim Biophys Acta; 2004 Jun; 1689(2):91-102. PubMed ID: 15196590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients.
    Witko-Sarsat V; Gausson V; Nguyen AT; Touam M; Drüeke T; Santangelo F; Descamps-Latscha B
    Kidney Int; 2003 Jul; 64(1):82-91. PubMed ID: 12787398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in glycation and oxidation markers in patients starting peritoneal dialysis: a pilot study.
    Boulanger E; Moranne O; Wautier MP; Witko-Sarsat V; Descamps-Latscha B; Kandoussi A; Grossin N; Wautier JL
    Perit Dial Int; 2006; 26(2):207-12. PubMed ID: 16623427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are advanced oxidation protein products potential uremic toxins?
    Witko-Sarsat V; Gausson V; Descamps-Latscha B
    Kidney Int Suppl; 2003 May; (84):S11-4. PubMed ID: 12694298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A central role for intermolecular dityrosine cross-linking of fibrinogen in high molecular weight advanced oxidation protein product (AOPP) formation.
    Colombo G; Clerici M; Giustarini D; Portinaro N; Badalamenti S; Rossi R; Milzani A; Dalle-Donne I
    Biochim Biophys Acta; 2015 Jan; 1850(1):1-12. PubMed ID: 25280629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The advanced glycation endproduct pentosidine and monocyte activation in uremia.
    Friedlander MA; Witko-Sarsat V; Nguyen AT; Wu YC; Labrunte M; Verger C; Jungers P; Descamps-Latscha B
    Clin Nephrol; 1996 Jun; 45(6):379-82. PubMed ID: 8793229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased level of advanced oxidation protein products in patients with coronary artery disease.
    Kaneda H; Taguchi J; Ogasawara K; Aizawa T; Ohno M
    Atherosclerosis; 2002 May; 162(1):221-5. PubMed ID: 11947918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of pregnancy-associated plasma protein-a to renal function and dialysis modalities.
    Fialová L; Kalousová M; Soukupová J; Sulková S; Merta M; Jelínková E; Horejsí M; Srámek P; Malbohan I; Mikulíková L; Tesar V; Zima T
    Kidney Blood Press Res; 2004; 27(2):88-95. PubMed ID: 14739577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors.
    Valli A; Suliman ME; Meert N; Vanholder R; Lindholm B; Stenvinkel P; Watanabe M; Barany P; Alvestrand A; Anderstam B
    Clin Chim Acta; 2007 Apr; 379(1-2):87-94. PubMed ID: 17292872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of the oxidative stress biomarker AOPP assay: application in uremic samples.
    Anderstam B; Ann-Christin BH; Valli A; Stenvinkel P; Lindholm B; Suliman ME
    Clin Chim Acta; 2008 Jul; 393(2):114-8. PubMed ID: 18423381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome?
    Selmeci L
    Free Radic Res; 2011 Oct; 45(10):1115-23. PubMed ID: 21740311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced Oxidation Protein Products-Modified Albumin Induces Differentiation of RAW264.7 Macrophages into Dendritic-Like Cells Which Is Modulated by Cell Surface Thiols.
    Garibaldi S; Barisione C; Marengo B; Ameri P; Brunelli C; Balbi M; Ghigliotti G
    Toxins (Basel); 2017 Jan; 9(1):. PubMed ID: 28075404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients.
    Nguyen-Khoa T; Massy ZA; Witko-Sarsat V; Thévenin M; Touam M; Lambrey G; Lacour B; Drüeke TB; Descamps-Latscha B
    Kidney Int; 1999 Aug; 56(2):747-53. PubMed ID: 10432417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure.
    Miyata T; Wada Y; Cai Z; Iida Y; Horie K; Yasuda Y; Maeda K; Kurokawa K; van Ypersele de Strihou C
    Kidney Int; 1997 Apr; 51(4):1170-81. PubMed ID: 9083283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of resveratrol on glycation and oxidation products in plasma and liver of chronic methylglyoxal-treated rats.
    Yılmaz Z; Kalaz EB; Aydın AF; Olgaç V; Doğru-Abbasoğlu S; Uysal M; Koçak-Toker N
    Pharmacol Rep; 2018 Jun; 70(3):584-590. PubMed ID: 29679882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolipodialysis attenuates oxidative stress and removes hydrophobic toxins.
    Wratten ML; Sereni L; Tetta C
    Artif Organs; 2000 Sep; 24(9):685-90. PubMed ID: 11012537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP).
    Iwao Y; Anraku M; Hiraike M; Kawai K; Nakajou K; Kai T; Suenaga A; Otagiri M
    Drug Metab Pharmacokinet; 2006 Apr; 21(2):140-6. PubMed ID: 16702734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease.
    Drüeke T; Witko-Sarsat V; Massy Z; Descamps-Latscha B; Guerin AP; Marchais SJ; Gausson V; London GM
    Circulation; 2002 Oct; 106(17):2212-7. PubMed ID: 12390950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.